Genmab — November 2017
-
Prisen på udløbne patenterede produkter stiger, fordi efterspørgselselasticiteten hos de tilbageværende forbrugere er lavere end den var hos de samlede forbrugere tidligere. Typisk gamle mennesker tøt ikke skifte til de generiske, og man skulle tro alle kunne være enige om at det er deres eget problem.
-
twitter: Leon @ldyer112
Yes you got it Daratumumab costs 37k for 2 months supply trying to get the money together but it’s hard hoping the hospital commission will push this through for her as I got NICE to write to me saying that don’t object to it’s use but it just haven’t finished the approval proces 19:04 - 13 nov.
-
God morgen.
-
Fik nogen opsnuset, hvad der skete ifht patentsagen i US i går? Jky linkede til finans.dk
-
Der var ingen respons fra "panelet" JV. I dag har NP denne (gentagelse) https://npinvestor.dk/nyheder/korr-genmab-får-delsejr-i-patenttvist-citat
-
Men var det ikke med den modsatte "holdning" i går- at det gik Genmab imod
-
Jeg var jp erhverv igennem her til morgen, og der var ikke noget
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind